3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Doxorubicin
7
pembrolizumab
5
Radiotherapy
5
Specimen Handling
4
Radiation
4
Magnetic Resonance Spectroscopy
4
palbociclib
3
eribulin
3
abemaciclib
3
Ifosfamide
3
Biopsy
3
pazopanib
2
brigimadlin
2
Immunoglobulin G
2
zimberelimab
1
toripalimab
1
talimogene laherparepvec
1
silmitasertib
1
selinexor
1
ribociclib
1
peposertib
1
pemigatinib
1
olaratumab
1
olaparib
1
mirdametinib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
durvalumab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
Histamine H2 Antagonists
×
1 year
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled